Clinical trials: Moderate COVID-19-infection
SARS-COV-2 Infections, COVID-19
Fight COVID-19 Trial
A 6-Week Prospective, Open label, Randomized, in Multicenter Study of, Oseltamivir 300mg per day plus Hydroxychloroquine 800 mg per day versus Combination of Lopipinavir 800mg (or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5…
- Trial name
- FIGHT-COVID-19 (NCT04303299)
- Testing
- Oral
- Where
- Thailand
- Volunteers
- 320 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Covid19
Impact of Moderate Exercise Training on Vitals and Peak VO2 in Different Age Categories of Adult in COVID-19.
To determine the impact of moderate exercise training on vitals (BP, HR) in different age categories of adult in COVID-19. To determine the Impact of moderate exercise training on Peak VO2 in different age categories of adult in…
- Trial name
- NCT04927182
- Testing
- Moderate Exercise Training (Age Group 1; Young adult 17 -30 years), Moderate Exercise Training (Age Group 2; 31 to 45 years), Moderate Exercise Training (Age Group 3; Above 45 years)
- Where
- Pakistan
- Volunteers
- 102 people
- Sponsor
- Riphah International University
Mental Health Wellness 1, COVID
Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19
A pragmatic superiority randomized controlled trial comparing Telepsychoeducation plus personalized videos vs. Telepsychoeducation without personalized videos for the prevention of future emotional distress in professionals and…
- Conditions
- Mental Health Wellness 1, COVID, Emotional Distress, Depressive Symptoms
- Trial name
- NCT04632082
- Testing
- Telepsychoeducation with personalized videos, Telepsychoeducation without personalized videos
- Where
- Brazil
- Volunteers
- 2,200 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
COVID-19, Favipiravir
Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
This is an open-label, non-randomized clinical trial study. The number of 40 COVID-19 patients with moderate severity will be admitted in progressive care units (PCUs) and intensive care units (ICUs) enrolled in the study.
- Conditions
- COVID-19, Favipiravir, Kaletra, Hydroxychloroquine
- Trial name
- NCT04376814
- Testing
- Favipiravir, Hydroxychloroquine, Lopinavir / Ritonavir
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Baqiyatallah Medical Sciences University
COVID-19
Plasma Immunity of Mild SARS-CoV-2 Omicron and Delta Pandemic in Thailand
The investigators assessed the effect of treatment for COVID and immunity of the volunteers who admitted to the home isolation.
- Trial name
- NCT05328479
- Where
- Thailand
- Volunteers
- 5,181 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Coronavirus
Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.
In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, in China. In a few weeks, the number of confirmed cases of SARS-CoV-2 infection has dramatically increased, with almost 150'000…
- Trial name
- Cov-CONTACT (NCT04259892)
- Testing
- 2019-nCoV PCR
- Where
- 16 sites in France, French Guiana
- Volunteers
- 324 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
COVID-19
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
- Trial name
- NCT04486313
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 2 sites in United States
- Volunteers
- 935 people
- Sponsor
- Romark Laboratories L.C.
COVID-19
A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from getting worse. Participants with mild-to-moderate COVID-19 will receive bamlanivimab via an injection into a vein.
- Trial name
- BLAZE-5 (NCT04701658)
- Testing
- Bamlanivimab
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
COVID-19, Children
Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children
In the COVID-19 pandemic era, a convenient and effective treatment for pediatric patients is unavailable. A multi-center Chinese clinical trials with the aim to using Interferon-α2b spray inhalation to develop new treatment…
- Trial name
- NCT05381363
- Testing
- Inhaled Interferon α2b, Standard of Care
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Children's Hospital of Fudan University
COVID-19
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19.
- Trial name
- BLAZE-4 (NCT04634409)
- Testing
- Bamlanivimab, Etesevimab, VIR-7831
- Where
- 141 sites in United States, Argentina and 1 more
- Volunteers
- 1,755 people
- Sponsor
- Eli Lilly and Company
Coronavirus
Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID-19.
In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, in China. In a few weeks, the number of confirmed cases of SARS-CoV-2 infection has dramatically increased, with almost 150'000…
- Trial name
- NCT04322279
- Testing
- Serology, Sequencing
- Where
- 16 sites in France, French Guiana
- Volunteers
- 81 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Moderate COVID-19 Pneumonia, Severe COVID-19 Pneumonia, Pneumonia, Viral
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
Due to the limitations of COVID-19 treatment and in the absence of licensed antiviral for COVID-19, the historical choice of therapeutic convalescent plasma (CP) is considered especially against RNA viruses .It was known that…
- Trial name
- NCT04474340
- Testing
- COVID-19 Convalscent Plasma
- Where
- Kuwait
- Volunteers
- 300 people
- Sponsor
- Ministry of Health, Kuwait
Covid19
Vitamin A Supplementation in Children With Moderate to Severe COVID-19
Severe acute respiratory syndrome (SARS)-like coronavirus 2 (Sars-CoV-2) pandemia is considered to be the current major global health issue.
- Trial name
- NCT04920760
- Testing
- Vitamin A supplement
- Volunteers
- 60 people
- Sponsor
- Shiraz University of Medical Sciences
Covid19
Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting
No therapeutic agent is currently approved for the treatment of SARSCoV-2 infection. More importantly, no intervention is currently available to mitigate the progression of disease from mid/moderate to serve particularly in high…
- Trial name
- NCT04840459
- Testing
- BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB
- Where
- 3 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Sohail Rao
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
Corona Virus Infection
Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients
In current analysis moderate to severely ill Covid-19 infected patients will be nebulized with nitroglycerin, and they will be compared with the standard nebulization
- Trial name
- NCT04686760
- Testing
- Nitroglycerin
- Where
- Pakistan
- Volunteers
- 278 people
- Sponsor
- University of Lahore
Cytokine Release Syndrome, COVID19
Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
This protocol will evaluate the efficacy of Therapeutic Plasma Exchange (TPE) alone or in combination with ruxolitinib in COVID positive patients with PENN grade 2, 3, 4 cytokine release syndrome (CRS).
- Trial name
- NCT04374149
- Testing
- Therapeutic Plasma Exchange, Ruxolitinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Prisma Health-Upstate
COVID-19
Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
This Phase 2b study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of sotrovimab in pediatric participants from birth to less than (<)18 years old with mild-to-moderate Coronavirus Disease-2019…
- Trial name
- COMET-PACE (NCT05124210)
- Testing
- Sotrovimab
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
COVID-19, Long COVID
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e.
- Trial name
- MEADOWSPRING (NCT05059080)
- Where
- 35 sites in Argentina, Belgium and 8 more
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
COVID-19
Transcranial Non-invasive Electrical Stimulation of the Vagus Nerve in Hospitalized Moderate-to-severe COVID-19 Patients
Subtle Pulse Electro-biological Recovery Apparatus (SPERA) is an innovative device which delivers digital subliminal pulse stimulation trans cranially to auricular branches of the central nervous system and modulates the…
- Trial name
- NCT06767241
- Testing
- Non-invasive auricular vagus nerve stimulation, Standard Medical Therapy
- Where
- Romania
- Volunteers
- 83 people
- Sponsor
- University of Medicine and Pharmacy "Victor Babes" Timisoara